Catherine Kreatsoulas, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Headache Disorders, Primary | 1 | 2023 | 39 | 0.880 |
Why?
|
Men's Health | 2 | 2013 | 70 | 0.860 |
Why?
|
Women's Health | 4 | 2019 | 2057 | 0.830 |
Why?
|
Angina Pectoris | 3 | 2013 | 970 | 0.720 |
Why?
|
Estrogen Replacement Therapy | 2 | 2019 | 1207 | 0.670 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2019 | 131 | 0.620 |
Why?
|
Menopause | 2 | 2019 | 1640 | 0.600 |
Why?
|
Strabismus | 1 | 2021 | 317 | 0.540 |
Why?
|
Coronary Angiography | 5 | 2021 | 4559 | 0.510 |
Why?
|
Social Class | 3 | 2015 | 2005 | 0.510 |
Why?
|
Disabled Persons | 1 | 2023 | 1226 | 0.450 |
Why?
|
Coronary Artery Disease | 4 | 2021 | 6643 | 0.430 |
Why?
|
Cardiovascular Diseases | 9 | 2024 | 15726 | 0.370 |
Why?
|
Selection Bias | 1 | 2009 | 358 | 0.290 |
Why?
|
Income | 1 | 2015 | 1876 | 0.280 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1395 | 0.270 |
Why?
|
Primary Prevention | 1 | 2013 | 1203 | 0.250 |
Why?
|
Referral and Consultation | 2 | 2017 | 3598 | 0.200 |
Why?
|
Sex Factors | 4 | 2021 | 10515 | 0.180 |
Why?
|
Coronary Disease | 3 | 2024 | 5989 | 0.160 |
Why?
|
Diabetic Angiopathies | 2 | 2017 | 822 | 0.160 |
Why?
|
Poverty | 1 | 2010 | 2679 | 0.160 |
Why?
|
Risk Factors | 9 | 2023 | 74167 | 0.150 |
Why?
|
Wounds, Gunshot | 1 | 2024 | 581 | 0.150 |
Why?
|
Chronic Disease | 1 | 2013 | 9245 | 0.150 |
Why?
|
Delphi Technique | 1 | 2021 | 818 | 0.150 |
Why?
|
Acute Coronary Syndrome | 1 | 2010 | 2363 | 0.140 |
Why?
|
Decision Making | 1 | 2010 | 3917 | 0.140 |
Why?
|
Firearms | 1 | 2024 | 625 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2013 | 10329 | 0.130 |
Why?
|
Prevalence | 4 | 2024 | 15639 | 0.130 |
Why?
|
Needs Assessment | 2 | 2019 | 1137 | 0.130 |
Why?
|
Headache | 1 | 2023 | 1249 | 0.130 |
Why?
|
Canada | 2 | 2010 | 2124 | 0.120 |
Why?
|
Research Design | 2 | 2017 | 6165 | 0.120 |
Why?
|
Preventive Health Services | 1 | 2019 | 571 | 0.110 |
Why?
|
Spironolactone | 1 | 2017 | 411 | 0.110 |
Why?
|
Ontario | 3 | 2009 | 404 | 0.100 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2267 | 0.100 |
Why?
|
Sweating | 1 | 2013 | 154 | 0.100 |
Why?
|
Humans | 25 | 2024 | 759098 | 0.100 |
Why?
|
Gallbladder Diseases | 1 | 2013 | 137 | 0.100 |
Why?
|
Pacemaker, Artificial | 1 | 2018 | 815 | 0.100 |
Why?
|
Female | 18 | 2024 | 390174 | 0.100 |
Why?
|
Middle Aged | 12 | 2024 | 219628 | 0.090 |
Why?
|
Food Supply | 1 | 2017 | 530 | 0.090 |
Why?
|
Consensus | 1 | 2021 | 3091 | 0.090 |
Why?
|
Aortic Diseases | 1 | 2017 | 736 | 0.090 |
Why?
|
Aorta, Thoracic | 1 | 2017 | 1094 | 0.090 |
Why?
|
Developing Countries | 2 | 2015 | 2862 | 0.090 |
Why?
|
Muscle Weakness | 1 | 2013 | 413 | 0.090 |
Why?
|
Male | 16 | 2024 | 358602 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2015 | 7790 | 0.080 |
Why?
|
Population Groups | 1 | 2010 | 211 | 0.080 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2001 | 465 | 0.080 |
Why?
|
Urinary Incontinence | 1 | 2013 | 495 | 0.080 |
Why?
|
Risk Assessment | 2 | 2021 | 24049 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2610 | 0.080 |
Why?
|
Heart | 1 | 2021 | 4391 | 0.080 |
Why?
|
United States | 6 | 2024 | 72238 | 0.070 |
Why?
|
Educational Status | 1 | 2015 | 2512 | 0.070 |
Why?
|
Arrhythmias, Cardiac | 1 | 2018 | 2253 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2891 | 0.070 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2001 | 638 | 0.070 |
Why?
|
Developed Countries | 1 | 2010 | 439 | 0.070 |
Why?
|
Aged | 9 | 2024 | 168615 | 0.070 |
Why?
|
Chest Pain | 1 | 2013 | 1106 | 0.070 |
Why?
|
Fatigue | 1 | 2013 | 1543 | 0.060 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2004 | 1880 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1352 | 0.060 |
Why?
|
Aortic Valve Stenosis | 1 | 2018 | 2066 | 0.060 |
Why?
|
Epidemiologic Methods | 1 | 2009 | 1341 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2009 | 782 | 0.060 |
Why?
|
Neoplasms | 1 | 2013 | 22023 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1317 | 0.060 |
Why?
|
Cost of Illness | 1 | 2013 | 1937 | 0.060 |
Why?
|
Life Expectancy | 1 | 2010 | 1248 | 0.050 |
Why?
|
Age Factors | 2 | 2010 | 18391 | 0.050 |
Why?
|
Survivors | 1 | 2013 | 2355 | 0.050 |
Why?
|
Creatine Kinase | 1 | 2004 | 691 | 0.050 |
Why?
|
Public Health | 1 | 2015 | 2656 | 0.050 |
Why?
|
Cities | 1 | 2024 | 538 | 0.050 |
Why?
|
Curriculum | 1 | 2015 | 3710 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2017 | 3525 | 0.050 |
Why?
|
Stroke | 2 | 2024 | 9936 | 0.050 |
Why?
|
Fractures, Bone | 1 | 2013 | 2035 | 0.050 |
Why?
|
Primary Health Care | 1 | 2017 | 4638 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2018 | 58864 | 0.040 |
Why?
|
Young Adult | 2 | 2019 | 58477 | 0.040 |
Why?
|
Troponin I | 1 | 2004 | 634 | 0.040 |
Why?
|
Coronary Care Units | 1 | 2001 | 235 | 0.040 |
Why?
|
Mental Health | 1 | 2013 | 3195 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2019 | 21019 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2001 | 3193 | 0.040 |
Why?
|
Stress, Psychological | 1 | 2013 | 4429 | 0.040 |
Why?
|
Schools, Public Health | 1 | 2015 | 22 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15662 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2018 | 848 | 0.030 |
Why?
|
Prognosis | 3 | 2013 | 29559 | 0.030 |
Why?
|
Incidence | 4 | 2024 | 21344 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20027 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2001 | 9131 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2023 | 2035 | 0.030 |
Why?
|
Depression | 1 | 2013 | 8026 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 12270 | 0.030 |
Why?
|
Smoking | 1 | 2009 | 9066 | 0.030 |
Why?
|
Prospective Studies | 2 | 2017 | 54190 | 0.030 |
Why?
|
Organ Size | 1 | 2018 | 2247 | 0.030 |
Why?
|
Cohort Studies | 2 | 2013 | 41266 | 0.030 |
Why?
|
Work | 1 | 2013 | 194 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 2001 | 2106 | 0.020 |
Why?
|
Internal-External Control | 1 | 2013 | 359 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2017 | 1438 | 0.020 |
Why?
|
Myocardial Infarction | 2 | 2004 | 11891 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2018 | 2123 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36164 | 0.020 |
Why?
|
Hypertension | 1 | 2009 | 8582 | 0.020 |
Why?
|
Ventricular Remodeling | 1 | 2017 | 1252 | 0.020 |
Why?
|
Hemorrhage | 1 | 2001 | 3606 | 0.020 |
Why?
|
Adult | 3 | 2024 | 219353 | 0.020 |
Why?
|
Aortic Valve | 1 | 2018 | 1994 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2017 | 15262 | 0.020 |
Why?
|
Plaque, Atherosclerotic | 1 | 2017 | 1517 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4268 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 3854 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 25853 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2017 | 12383 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8788 | 0.010 |
Why?
|
Pilot Projects | 1 | 2015 | 8530 | 0.010 |
Why?
|
Health Behavior | 1 | 2013 | 2619 | 0.010 |
Why?
|
Hematocrit | 1 | 2001 | 630 | 0.010 |
Why?
|
Postoperative Period | 1 | 2004 | 1823 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2001 | 1384 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10550 | 0.010 |
Why?
|
Hemoglobins | 1 | 2001 | 1517 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2017 | 64867 | 0.010 |
Why?
|
Child, Preschool | 1 | 2017 | 41932 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23328 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2004 | 6814 | 0.010 |
Why?
|
Quality of Life | 1 | 2013 | 13285 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 10181 | 0.010 |
Why?
|
Child | 1 | 2017 | 79604 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2001 | 12526 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2001 | 80125 | 0.000 |
Why?
|